Conclusions  Preclinical data suggest an ocular surface-expressed TF-dependent phenomenon and provide potential mechanistic rationale which may partly contribute to the inflammatory and symptomatic nature of clinically observed TV-associated OAEs. Clinical trial experience suggests adherence to required eye care and appropriate dose modifications reduce risk and severity of OAEs.

LAPAROSCOPIC RADICAL HYSTERECTOMY IS SAFE IN CERVICAL CANCER WITH TUMOR SIZE ≤2 CM, EVEN IF PARAMETRIAL INVASION OR LYMPH NODE METASTASIS IS FOUND AFTER SURGERY

Anup P. Singh, 1Naery Kim*, 1Se Ik Kim, 2Dong Hoon Suh, 1Hee Seung Kim, 3Ki Dong Kim, 2Hyun Hoon Chung, 1Jae Hong No, 1Yong Beom Kim, 1Jae-Weon Kim, 3Noh Hyun Park, 1Yang-Sang Song, 1Chel Hun Choi, 1Maria Lee. 2Seoul national university hospital, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 3Seoul National University College of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; 3Seoul National University Bundang Hospital, Obstetrics and Gynecology, Seongnam, Korea, Republic of; 1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of.

Objective: Previously our research team suggested cervical cancer (CC) patients with tumor size ≤2 cm on preoperative magnetic resonance imaging (MRI) were safe candidates for laparoscopic radical hysterectomy (RH). We aimed to further investigate whether laparoscopic RH is feasible in patients with small-sized, early CC, having high-risk pathologic factors.

Methods: From CC cohorts of three tertiary hospitals, we identified patients with 2009 FIGO stage IB1 who received open or laparoscopic Type C RH. Among them, those with tumor size ≤2 cm on preoperative MRI and who followed the guidelines for adjuvant treatment were included. Patients’ survival outcomes were compared between the laparoscopic and open RH groups. Subgroup analyses were conducted according to the parametrial invasion (PMI) and lymph node metastasis (LNM).

Results: A total of 498 patients were included: 299 and 199 for laparoscopic and open RH groups, respectively. All study populations were managed properly in adjuvant treatment. After a median observation of 59.4 months, two groups showed similar progression-free survival (PFS; P=0.615) and overall survival (P=0.439). On pathologic examination, 16 (3.2%) and 49 (9.8%) had PMI and LNM, respectively, and 10 (2.0%) had both. In PMI subgroup, no progression was clinically but not statistically significant for type of disease (P=0.893) with no statistical significance between L1CAM positive and L1CAM negative tumors (P=0.766). Type of disease progression was clinically but not statistically significant for multiple and distant metastasis (p=0.11). Comparing of Progression free interval and Overall survival did not shown statistical significance.

Conclusions: In our study L1CAM is only clinically significant factor for distant type of recurrence and worse prognosis, but not statistically significant.

Abstracts

EP065/#654

L1CAM AS PROGNOSTIC FACTOR FOR TYPE OF RECURRENCE IN EARLY-STAGE SQUAMOUS CELL CERVICAL CANCER PATIENTS

1Jaroslav Klát*, 1Marina Romanova, 2Sylva Bajova, 3Vladimir Židík, 1Ondřej Smetka. 1University Hospital Ostava, Ostrava, Ostrava, Czech Republic; 2University Hospital Ostava, Pathology, Ostrava, Czech Republic

Objectives: L1CAM belongs to the immunoglobulin superfamily of cell adhesion molecules. In cancer cells, L1CAM promotes cell proliferation, migration, invasion, and metastasis. Its expression is associated with tumor progression in many types of cancer, including colorectal, gastric, renal, endometrial and breast cancer. In this study, we aimed to investigate how L1 cell adhesion molecule (L1CAM) positivity was associated with outcome and relapse pattern in early-stage stage cervical cancer.

Methods: This is retrospective study. Total number of 251 patients who underwent surgical treatment for early-stage cervical carcinoma were enrolled into the study. Patients who underwent a minimally invasive procedure were excluded from the study. Tumor samples of 191 (76,1%) patients were available for L1CAM analysis by immunohistochemistry and total number of patients with squamous histology was 144.

Results: Of the 144 tumor samples, 21 (14,6%) were found to be L1CAM positive. Recurrence was observed in 20 patients (13,8%) with no statistical significance between L1CAM positive and L1CAM negative tumors (p=0.766). Type of disease progression was clinically but not statistically significant for multiple and distant metastasis (p=0.11). Comparing of Progression free interval and Overall survival did not show statistical significance.

Conclusions: In our study L1CAM is only clinically significant factor for distant type of recurrence and worse prognosis, but not statistically significant.

EP067/#802

A COMPARISON OF ADVERSE OUTCOMES WITH THE USE OF BEVACIZUMAB WITH CISPLATIN/PACLITAXEL OR CARBOPLATIN/PACLITAXEL IN RECURRENT, PERSISTENT OR METASTATIC CERVICAL CANCER

1Maryam Kotait*, 2Tessa Anzai, 3Rosa Chow, 4Clare Reade, 4Vanessa Carlson, 6Luu Einiksson, 6Waldo Jimenez, 6Julie Nguyen. 1McMaster University, Obstetrics & Gynecology, Hamilton, Canada; 2McMaster University, Michael G. DeGroote School of Medicine, Hamilton, Canada; 3McMaster University, Pharmacy, Hamilton, Canada; 4Juravinski Cancer Centre, Gynecologic Oncology, Hamilton, Canada

Objectives: Background: GOG-240 demonstrated improved oncologic outcomes with addition of bevacizumab to standard chemotherapy for metastatic or recurrent cervical carcinoma. Previously, JCOG0505 revealed non-inferior oncologic outcomes of carboplatin/paclitaxel(TC) compared to cisplatin/paclitaxel(TP). However, there is no recent data comparing adverse events and chemotherapy response rates between TC and TP.
since addition of bevacizumab. Objective: To compare adverse events and response to chemotherapy of patients with metastatic or recurrent non-resectable cervical carcinoma who initiated chemotherapy between 01/2015 and 09/2021 with carboplatin/paclitaxel/bevacizumab (TCB) or cisplatin/paclitaxel/bevacizumab (TPB).

Methods A retrospective study was conducted. Adverse events were classified using the National Cancer Institute Common Terminology Criteria for Adverse Events.

Results Forty-seven patients were included; 29 with squamous cell histology and 18 with adenocarcinoma or adenosquamous histology. Median follow-up was 19 months. Thirty-eight patients received TCB, 9 received TPB; 19 were treated for metastatic disease, 3 for persistent disease, and 26 for recurrent disease. Median number of chemotherapy cycles was 6. While response to chemotherapy was similar in both groups (stable disease 13.2% vs 33.3%, p=0.15, partial or complete response, 36.8% vs 33.3%, p=0.84), patients receiving TCB experienced significantly less grade 3–5 (26.3% vs 66.7%, p=0.02) and grade 1–2 adverse events (13.2% vs 55.6%, p=0.005). Bevacizumab was discontinued in 12 patients (25.5%) due to severe toxicity, with significantly greater rate of fistula and perforation compared to rates in GOG 240 (12.8% vs 3%, p=0.004).

Conclusions In this cohort, patients receiving TCB had similar response to chemotherapy, but significantly less adverse events, than those receiving TPB. Bevacizumab confers a high risk of severe adverse events.

Abstract EP069/#855 Figure 1

COMPREHENSIVE PROFILING OF CERVIX CANCER PATIENTS USING TUMOR NEXT-GENERATION SEQUENCING (NGS) AND IMMUNOHISTOCHEMISTRY (IHC)

Lee Kyunglim*, Yoo-Na Kim, Jung-Yun Lee, Sang Wun Kim, Sunghoon Kim, Eun Ji Nam, Yong Jae Lee, Young Tae Kim. Severance hospital, Seodaemun-gu, Seoul, Korea, Republic of

Objectives To investigate the landscape of genomic alterations and immunohistochemistry based targetable characteristics in cervix cancer patients.

Methods Cervix cancer patients who underwent tumor NGS using TruSight Oncology 500 were analyzed. Clinical information including history, stage, HPV genotype, serum tumor marker, IHC profile, and therapy outcome were reviewed. PD-L1 positive was defined as having CPS of 10 or higher based on 22C3 antibody.

Results A total of 63 cervix cancer patients with predominantly advanced stage disease (III and above, 62%) were identified. Among 26 patients tested for HPV genotype, 16 and 18 were the most common (21% and 13%, respectively). PD-L1 positive was identified in 8 out of 38 tested (20.5%). With respect to histology, PD-L1 positivity was 41% for SCC and 4.5% for non-SCC (p-value = 0.01). Among 63 patients, alteration in SNV was found in 49 patients (78%) and CNV in 10 patients (16%). Most SNV altered gene were